Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€14.84

€14.84

0.680%
0.1
0.680%
-

-

 
26.04.24 / Tradegate WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Your prediction

Abivax S.A. Stock

Abivax S.A. gained 0.680% compared to yesterday.
Our community identified positive and negative aspects for Abivax S.A. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Abivax S.A. stock. On the other hand our users think that "Valuation (undervalued/overvalued)" could be a problem in the future.

Pros and Cons of Abivax S.A. in the next few years

Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Abivax S.A. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Abivax S.A. 0.680% - - - - - -
Valneva SE 0.800% -2.718% -4.127% -18.057% -26.442% -69.549% 3.787%
Nanobiotix 0.280% 4.106% -4.570% 157.869% -17.056% -59.902% -53.534%
Transgene S.A. 1.430% -10.526% 15.625% -29.799% -6.119% -49.376% -56.471%

Comments

Prediction Buy
Perf. (%) 82.50%
Target price 6.970
Change
Ends at 14.09.16

(Zielkurs erreicht)
Show more

Prediction Buy
Perf. (%) 82.50%
Target price 6.970
Change
Ends at 14.09.16

DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu

DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.
Show more

News

EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
EQS-News: Abivax reports 2023 financial results and operational update
EQS-News: Abivax reports 2023 financial results and operational update
EQS-News: Abivax reports 2023 financial results and operational update
EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)